Funder: National Institutes of Health (NIH)
Due Dates: October 6, 2025 (Final cycle for this PAR)
Funding Amounts: Phase I: up to $295,924 (1 year) | Phase II: up to $1,972,828 (2 years); higher budgets possible with waiver approval
Summary: Supports U.S. small businesses developing novel extracellular vesicle-based therapeutic platforms for regenerative medicine, focusing on technology for production, manufacturing, and use of EVs as therapeutics.
Key Information: Clinical trials are not allowed; foreign entities are not eligible; strict SBIR/STTR eligibility and disclosure requirements apply.